Novo Nordisk: Watching Value Investors Buy The Dip Hurts My Eyes

Novo Nordisk (NVO) has significantly revised down its FY2025 guidance, projecting sales to decrease by 8-14% CER and operating profit by 10-16%, attributing this to market share erosion in its U.S. GLP-1 and weight-loss segments, particularly Wegovy's underperformance against tirzepatide. This outlook has led to a downgrade to a 'Hold' rating, with expectations for the stock to consolidate around $50 for the remainder of the year, despite the potential future impact of its oral semaglutide 25 mg pill currently under FDA review.

Analysis

Novo Nordisk has issued a significant downward revision to its FY2025 guidance, projecting an 8-14% decline in sales and a 10-16% drop in operating profit on a constant exchange rate basis. This negative outlook is driven by observable market share erosion in the critical U.S. weight-loss market, where its GLP-1 products Wegovy and Ozempic are facing intensified competition. Notably, Wegovy is lagging behind Eli Lilly's tirzepatide, confirming the primary thesis of the analyst's previous 'Strong Sell' rating. In light of these headwinds and expectations for flat growth, the stock is now rated 'Hold' with an anticipated consolidation around the $50 level for the back half of the year. While a potential catalyst exists with the company's oral semaglutide 25 mg pill, which demonstrated a 13.6% weight loss in trials, its FDA decision is not expected until Q4 2025, leaving its near-term contribution to sentiment and financials highly uncertain.

Key Decisions for Investors

• Investors should reassess forward-looking models for Novo Nordisk to account for the substantial FY2025 guidance reduction, which signals a period of negative growth and justifies a more cautious valuation.
• Closely monitor market share data within the U.S. GLP-1 drug segment, as continued share loss by Wegovy to Eli Lilly's tirzepatide is the primary risk factor underpinning the current neutral outlook.
• Consider the oral semaglutide pill a long-term, speculative catalyst, but avoid factoring it into near-term valuations given the distant Q4 2025 FDA decision timeline and uncertain market adoption dynamics.